Congress stock trackers flagged a sizable filing this week: Rep. Jefferson Shreve, who represents Indiana in the House, disclosed a personal purchase of a JPMorgan structured note worth between $5,000,001 and $25,000,000. The transaction was reported in a Periodic Transaction Report filed under the STOCK Act, the federal law requiring lawmakers to publicly disclose trades made by themselves, their spouses, or dependent children within 45 days.
The asset itself is a bit more exotic than the usual stock or ETF that shows up in these filings. It’s listed as a ‘JP Morgan 3-year one-time callable barrier note,’ a type of structured note that combines features of a bond and a derivative. These instruments typically pay a set return tied to the performance of an underlying index or basket of stocks, with built-in downside barriers and a call feature that lets the issuer redeem the note early. Shreve’s own filing describes the transaction simply as a ‘Structured Note.’
According to the disclosure, the purchase was made through an Advisory Account that holds Structured Notes, suggesting this isn’t a one-off buy but part of a broader allocation strategy managed alongside similar instruments. The transaction date listed is December 30, 2025.
What the Filing Does and Doesn’t Say
Whoisbuyingnow.com classifies this filing as a ‘congress buy’ signal, meaning it represents new money going into an asset rather than a sale or exit. The dollar range disclosed, $5,000,001 to $25,000,000, is one of the higher bands used on House financial disclosure forms, which report transactions in broad brackets rather than exact dollar figures. That means the real amount invested could be anywhere within that multi-million-dollar range.
It’s worth repeating what this filing is, and isn’t. A STOCK Act disclosure is a legally required paperwork filing, not an indication of wrongdoing or special knowledge. Members of Congress, like anyone else, buy structured notes, stocks, and other securities through advisory accounts, and the law simply requires that the public be told when they do. Nothing in this filing suggests illegality, and nothing here should be read as a recommendation to buy or sell anything mentioned.
Still, filings like this one tend to draw attention from readers who follow congressional trading activity closely, whether out of curiosity about which members hold complex financial products or simply to see how officials are positioning significant sums of money. A callable structured note tied to JPMorgan, held in a dedicated advisory account, is a less common entry in these disclosures than the typical index fund or blue-chip stock buy, which is part of what makes this one stand out.